Trademark: 98105723
Word
CAR-PLT
Status
Pending
Status Code
661
Status Date
Tuesday, July 16, 2024
Serial Number
98105723
Mark Type
4
Filing Date
Thursday, July 27, 2023

Trademark Owner History

Classifications
5 Medicinal infusions for treating viral, inflammatory, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary dysfunction, oncological, hematological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological and immune system related diseases and disorders, blood disorders, cancers, and fibrotic and neurodegenerative diseases; Drugs for medical purposes, namely, pharmaceutical preparations for treating viral, inflammatory, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary dysfunction, oncological, hematological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological and immune system related diseases and disorders, blood disorders, cancers, and fibrotic and neurodegenerative diseases; Therapeutic drugs and agents, namely, pharmaceutical preparations for treating viral, inflammatory, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary dysfunction, oncological, hematological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological and immune system related diseases and disorders, blood disorders, cancers, and fibrotic and neurodegenerative diseases; Pharmaceutical preparations for treating viral, inflammatory, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary dysfunction, oncological, hematological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological and immune system related diseases and disorders, blood disorders, cancers, and fibrotic and neurodegenerative diseases; Drug delivery agents in the form of infusion bags, infusion bags filled with platelets, infusion bags filled with platelets in suspension ready for infusion, infusion bags filled with lyophilized platelets, infusion bags filled with lyophilized platelets to be resuspended before infusion, infusion bags filled with cryopreserved platelets, infusion bags filled with cryopreserved platelets to be thawed prior to infusion that facilitate the delivery of proteins, peptides, long and short RNA, siRNA, miRNA, and saRNA; Drug delivery agents in the form of infusion bags, infusion bags filled with platelets, infusion bags filled with platelets in suspension ready for infusion, infusion bags filled with lyophilized platelets, infusion bags filled with lyophilized platelets to be resuspended before infusion, infusion bags filled with cryopreserved platelets, infusion bags filled with cryopreserved platelets to be thawed prior to infusion consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Medicines for treating viral, inflammatory, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary dysfunction, oncological, hematological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological and immune system related diseases and disorders, blood disorders, cancers, and fibrotic and neurodegenerative diseases; Pre-filled syringes and infusion bags for medical purposes featuring pharmaceutical preparations for treating viral, inflammatory, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary dysfunction, oncological, hematological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological and immune system related diseases and disorders, blood disorders, cancers, and fibrotic and neurodegenerative diseases; Drug delivery agents infused in a patient's blood consisting of compounds that facilitate delivery of a wide range of pharmaceuticals
44 Platelet-rich plasma therapy; blood banks
42 Testing and analysis of blood plasma, red blood cells, white blood cells, blood platelets for scientific research purposes

Trademark Events
Jul 31, 2023
New Application Entered
Aug 21, 2023
Teas Voluntary Amendment Received
Aug 28, 2023
New Application Office Supplied Data Entered
Jan 12, 2024
Assigned To Lie
Jan 12, 2024
Preliminary/Voluntary Amendment - Entered
Mar 28, 2024
Assigned To Examiner
Apr 17, 2024
Non-Final Action Written
Apr 17, 2024
Non-Final Action E-Mailed
Apr 17, 2024
Notification Of Non-Final Action E-Mailed
Jul 16, 2024
Teas/Email Correspondence Entered
Jul 16, 2024
Correspondence Received In Law Office
Jul 16, 2024
Teas Response To Office Action Received

Trademark Alertz updated from USPTO on 2030-01-24